Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors.

Months of escalating political pressure have put insulin manufacturers at the forefront of a move away from drug rebates. Eli Lilly and Co. (NYSE:LLY) announced Monday it would

Read the full 606 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE